A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

NCT06174766 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 324

Last updated 2025-06-12

No results posted yet for this study

Summary

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension

Conditions

Interventions

DRUG

HGP2102-1

Test drug

DRUG

HGP2102-2

Test drug

DRUG

RLD2209-1

Control drug

DRUG

RLD2209-2

Control drug

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-10
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • South Korea

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06174766 on ClinicalTrials.gov